FATE - FATE THERAPEUTICS INC

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 4.06

Open

$ 4.25

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 4.06 - $ 4.49

52 Week Range

$ 1.63 - $ 8.83

Volume

2,025,167

Average Volume

Market Cap

399.55M

Beta (5Y Monthly)

$ 1.54

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-26-2024	12-31-2023	10-K
2	11-08-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-03-2023	03-31-2023	10-Q
5	02-28-2023	12-31-2022	10-K
6	11-03-2022	09-30-2022	10-Q
7	08-03-2022	06-30-2022	10-Q
8	05-04-2022	03-31-2022	10-Q
9	02-28-2022	12-31-2021	10-K
10	11-04-2021	09-30-2021	10-Q
11	08-04-2021	06-30-2021	10-Q
12	05-05-2021	03-31-2021	10-Q
13	02-24-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-05-2020	06-30-2020	10-Q
16	05-11-2020	03-31-2020	10-Q
17	03-02-2020	12-31-2019	10-K
18	11-05-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-07-2019	03-31-2019	10-Q
21	03-05-2019	12-31-2018	10-K
22	11-01-2018	09-30-2018	10-Q
23	08-06-2018	06-30-2018	10-Q
24	05-10-2018	03-31-2018	10-Q
25	03-05-2018	12-31-2017	10-K
26	11-01-2017	09-30-2017	10-Q
27	08-14-2017	06-30-2017	10-Q
28	05-15-2017	03-31-2017	10-Q
29	03-16-2017	12-31-2016	10-K
30	11-07-2016	09-30-2016	10-Q
31	08-08-2016	06-30-2016	10-Q
32	05-09-2016	03-31-2016	10-Q
33	03-03-2016	12-31-2015	10-K
34	11-03-2015	09-30-2015	10-Q
35	08-05-2015	06-30-2015	10-Q
36	05-07-2015	03-31-2015	10-Q
37	03-12-2015	12-31-2014	10-K
38	11-12-2014	09-30-2014	10-Q
39	08-12-2014	06-30-2014	10-Q
40	05-13-2014	03-31-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Fate Therapeutics Announces Presentation O...
05/03/2024 20:31:26

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Techn...

Wedbush Reiterates Neutral on Fate Therape...
04/23/2024 17:12:50

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $7 price target.

Fate Therapeutics To Present FT819 Proof-O...
04/22/2024 20:35:00

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Im...

Where Fate Therapeutics Stands With Analysts
04/11/2024 14:00:17

Needham Reiterates Hold on Fate Therapeutics
04/11/2024 10:09:37

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) with a Hold.

12-health-care-stocks-moving-in-wednesdays-after-market-session

12 Health Care Stocks Moving In Wednesday'...
04/10/2024 20:31:09

B of A Securities Maintains Underperform o...
03/28/2024 18:13:21

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ:FATE) with a Underperform and raises the price ta...

Fate Therapeutics Announces Pricing Of $10...
03/19/2024 12:45:53

Evaluating Fate Therapeutics: Insights Fro...
03/19/2024 12:00:21

HC Wainwright & Co. Reiterates Neutral on ...
03/19/2024 10:53:43

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $...

Cracking The Code: Understanding Analyst R...
02/27/2024 20:00:24

Barclays Maintains Overweight on Fate Ther...
02/27/2024 14:37:02

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $...

dominos-to-rally-more-than-15-here-are-10-top-analyst-forecasts-for-tuesday

Domino's To Rally More Than 15%? Here Are ...
02/27/2024 14:09:11

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Wedbush Maintains Neutral on Fate Therapeu...
02/27/2024 13:49:46

Wedbush analyst David Nierengarten maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and raises the price target from...

Oppenheimer Reiterates Perform on Fate The...
02/27/2024 12:39:27

Oppenheimer analyst Matthew Biegler reiterates Fate Therapeutics (NASDAQ:FATE) from Perform to Perform.

Recap: Fate Therapeutics Q4 Earnings
02/26/2024 21:10:09

Fate Therapeutics Q4 2023 GAAP EPS $(0.45)...
02/26/2024 21:09:48

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0...

Earnings Scheduled For February 26, 2024
02/26/2024 09:47:53

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on...

A Preview Of Fate Therapeutics's Earnings
02/23/2024 17:01:59

Fate Therapeutics Announces Initiation Of ...
01/08/2024 13:04:09